Published in:
01-02-2021 | Liver Transplantation | Original Article
Favorable Survival with Non-curative Treatments for Patients with Early-Stage Hepatocellular Carcinoma After Liver Transplant Denial
Published in: Digestive Diseases and Sciences | Issue 2/2021
Login to get accessAbstract
Background
Many patients are not candidates for liver transplant for non-tumor-related reasons including medical comorbidities and non-adherence. The prognosis of patients with hepatocellular carcinoma (HCC) who are not liver transplant candidates in the era of locoregional therapy (LRT) including y90 is not well defined.
Aims
This study seeks to evaluate outcomes and the natural history of early-stage HCC in patients who were denied liver transplant listing due to non-tumor reasons and instead were treated with LRT.
Methods
A retrospective evaluation was performed for all patients who completed liver transplant evaluation with their tumor within Milan criteria but were denied due to non-tumor reasons and were treated with LRT at a single tertiary referral center.
Results
The 61 patients included had a favorable overall survival, with a median survival 60.3 months (86.9% at 1 year and 52.7% at 5 years). Patients with Child–Pugh A cirrhosis (n = 34) had significantly longer overall survival compared to those with Child–Pugh B/C cirrhosis (median survival of 70.3 months versus 26.1 months, p = 0.005). Survival in patients with Child–Pugh A at 1, 3, and 5 years was 97%, 80%, and 73%, respectively, compared to 74%, 41%, and 31% in patients with Child–Pugh B/C.
Conclusions
In a small single-center cohort, patients with HCC who were denied liver transplant due to non-tumor reasons and underwent LRT and had Child–Pugh A cirrhosis had survival approaching the national average for patients who undergo liver transplantation. Patients with Child–Pugh B/C cirrhosis had significantly worse outcomes than those with Child–Pugh A.